Weak or absent evidence for the association of HLA-DR antigens with risk of thyroid carcinoma: A meta-analysis of observational studies

Tissue Antigens

Volumn 78, Issue 5, 2011, Pages 382-389

  Kamdi, A S ^a   Kandavalli, N B ^a   Emusu, D ^a   Jain, N ^b   Mamtani, M ^b   Porterfield, J R ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Lata Medical Research Foundation   (India)

^c University of Alabama at Birmingham   (United States)

Author keywords

Association; Human leukocyte antigen; Major histocompatibility complex; Meta analysis; Thyroid carcinoma

Indexed keywords

HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR11 ANTIGEN;

ARTICLE; CANCER RISK; DISEASE ASSOCIATION; HLA SYSTEM; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THYROID CARCINOMA;

ADULT; CASE-CONTROL STUDIES; FEMALE; HLA-DR ANTIGENS; HLA-DR SEROLOGICAL SUBTYPES; HLA-DR1 ANTIGEN; HUMANS; MALE; THYROID NEOPLASMS;

SCOPUS;

EID: 80053925605     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01754.x     Document Type: Article

References (47)

1. Brown RS. Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr 2009: 21: 523-8.
2. Eschler DC, Hasham A, Tomer Y. Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol. Epub 14 January 2011.
3. Fisfalen M, Franklin W, DeGroot L et al. Expression of HLA ABC and DR antigens in thyroid neoplasia and correlation with mononuclear leukocyte infiltration. J Endocrinol Invest 1990: 13: 41-8.
4. Goldsmith N, Dikman S, Bermas B, Davies T, Roman S. HLA class II antigen expression and the autoimmune thyroid response in patients with benign and malignant thyroid tumors. Clin Immunol Immunopathol 1988: 48: 161-73.
5. Ciric J, Beleslin-Nedeljkovic B. Differentiated thyroid carcinoma in previously manifested autoimmune thyroid disease. Srp Arh Celok Lek 2005: 133 (Suppl 1): 74-6.
6. Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol 2008: 19: 209-20.
7. Sulimani RA. Thyroid cancer coexisting with Hashimoto's thyroiditis at King Khalid University Hospital, Saudi Arabia. East Afr Med J 1996: 73: 767-8.
8. Sridama V, Hara Y, Fauchet R, DeGroot L. Association of differentiated thyroid carcinoma with HLA-DR7. Cancer 1985: 56: 1086-8.
9. Panza N, Del Vecchio L, Maio M et al. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens 1982: 20: 155-8.
10. Juhasz F, Balázs G, Stenszky V, Kozma L, Farid N. The relation of susceptibility to and biologic behavior of thyroid epithelial cell cancer to HLA-DR1. Cancer 1986: 58: 52-4.
11. Juhasz F, Boros P, Szegedi G et al. Immunogenetic and immunologic studies of differentiated thyroid cancer. Cancer 1989: 63: 1318-26.
12. Juhasz F, Kozma L, Stenszky V, Gyory F, Luckas G, Farid N. Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: a case of changing circumstances. Cancer 2005: 104: 1603-8.
13. Larsen B, Thompson C, Kwan A, Farid N. Lack of association of HLA with thyroid cancer. An effect of iodine sufficiency and safe environment? Tissue Antigens 1986: 28: 298-300.
14. Weissel M, Kainz H, Hoefer R, Mayr W. HLA-DR and differentiated thyroid cancer. Lack of association with the nonmedullary types and possible association with the medullary type. Cancer 1988: 62: 2486-8.
15. Ahuja S, Hoppe I, von Keyserlingk H, Ernst H. HLA and thyroid carcinoma. Exp Clin Endocrinol 1992: 99: 134-6.
16. Rigopoulou D, Martinez-Laso J, Martinez-Tello F et al. Both class I and class II HLA antigens are thyroid cancer susceptibility factors. Tissue Antigens 1994: 43: 281-5.
17. Porto T, Coelho I, Boavida J et al. Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. Clin Endocrinol (Oxf) 2006: 64: 179-83.
18. Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe Y, Hosoda Y. Familial occurrence of differentiated, nonmedullary thyroid carcinoma. World J Surg 1988: 12: 565-71.
19. Amoli MM, Yazdani N, Amiri P et al. HLA-DR association in papillary thyroid carcinoma. Dis Markers 2010: 28: 49-53.
20. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010: 22: 395-404.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986: 7: 177-88.
22. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002: 7: 51-61.
23. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009: 172: 137-59.
24. Gyory F, Balazs G, Nagy EV et al. Differentiated thyroid cancer and outcome in iodine deficiency. Eur J Surg Oncol 2004: 30: 325-31.
25. Mishra A, Mishra SK, Agarwal A, Das BK, Agarwal G, Gambhir S. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area. World J Surg 2002: 26: 153-7.
26. Woodruff SL, Arowolo OA, Akute OO, Afolabi AO, Nwariaku F. Global variation in the pattern of differentiated thyroid cancer. Am J Surg 2010: 200: 462-6.
27. Harach HR, Escalante DA, Onativia A, Lederer Outes J, Saravia Day E, Williams ED. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh) 1985: 108: 55-60.
28. Davies TF, Roman SH, Mackenzie WA, Goldsmith N, Dower SM, Piccinini LA. Thyroid cell MHC class II antigens: a perspective on the aetiology of autoimmune thyroid disease. Acta Endocrinol Suppl (Copenh) 1987: 281: 13-20.
29. Goldsmith NK, Dikman S, Bermas B, Davies TF, Roman SH. HLA class II antigen expression and the autoimmune thyroid response in patients with benign and malignant thyroid tumors. Clin Immunol Immunopathol 1988: 48: 161-73.
30. Nyulassy S, Hnilica P, Stefanovic J. The HL-A system and subacute thyroiditis. A preliminary report. Tissue Antigens 1975: 6: 105-6.
31. Buc M, Nyulassy S, Hnilica P, Busova B, Stefanovic J. The frequency of HLA-Dw1 determinant in subacute (de Quervain's) thyroiditis. Tissue Antigens 1979: 14: 63-7.
32. Farid NR, Stone E, Johnson G. Graves' disease and HLA: clinical and epidemiologic associations. Clin Endocrinol (Oxf) 1980: 13: 535-44.
33. Heward JM, Allahabadia A, Daykin J et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab 1998: 83: 3394-7.
34. Schleusener H, Schernthaner G, Mayr WR et al. HLA-DR3 and HLA-DR5 associated thyrotoxicosis-two different types of toxic diffuse goiter. J Clin Endocrinol Metab 1983: 56: 781-5.
35. *0301 allele in Graves disease. Am J Med Genet 2000: 95: 432-7.
36. *0301 (DR3) gene. J Exp Med 1996: 184: 1167-72.
37. Tandon N, Zhang L, Weetman AP. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol (Oxf) 1991: 34: 383-6.
38. Moens H, Farid NR, Sampson L, Noel EP, Barnard JM. Hashimoto's thyroiditis is associated with HLA-DRw3. N Engl J Med 1978: 299: 133-4.
39. *0301 haplotype and lack of association of two polymorphic sites at CTLA-4 gene with Hashimoto's thyroiditis in an Italian population. Thyroid 2001: 11: 171-5.
40. Thompson C, Farid NR. Post-partum thyroiditis and goitrous (Hashimoto's) thyroiditis are associated with HLA-DR4. Immunol Lett 1985: 11: 301-3.
41. Farid NR, Sampson L, Moens H, Barnard JM. The association of goitrous autoimmune thyroiditis with HLA-DR5. Tissue Antigens 1981: 17: 265-8.
42. Jo Y, Lee J, Li S et al. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer. Int J Cancer 2008: 122: 785-90.
43. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas. Verh Dtsch Ges Pathol 1997: 81: 82-96.
44. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998: 8: 1179-83.
45. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002: 21: 1559-73.
46. Matoba K, Iizuka N, Gondo T et al. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 2005: 115: 231-40.
47. Redondo M, Garcia J, Villar E et al. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003: 34: 1283-9.